Fate Therapeutics (FATE) Stock Price, Quote & News

Company Profile

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus eryt...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 875 1800

Website: www.fatetherapeutics.com

Address:

12278 Scripps Summit Drive, San Diego, United States

Nik7777 Dec. 4 at 10:46 PM

$FATE

0 · Reply

cta7978 Dec. 4 at 10:35 PM

$FATE Anyone see any significant catalysts before Q4 data?

0 · Reply

Tonyboner Dec. 4 at 9:31 PM

$FATE

0 · Reply

cta7978 Dec. 4 at 5:54 PM

$FATE There was a big pile-in about 30 days before ACR in late September, then a sharp sell off on the data. Next pile-in later this month for Q4 data in January?

0 · Reply

JSP_Dilution_Player Dec. 4 at 5:38 PM

$IPSC $FATE $TCRX all have ASH and funds into 2027. At least one should pop by Friday or Monday

0 · Reply

Portfoliovalue1 Dec. 4 at 2:42 PM

$FATE At least priced at 300-500 million market cap with current clinical results.

0 · Reply

Nik7777 Dec. 3 at 10:19 PM

$FATE 🚀

0 · Reply

Rocketman808 Dec. 3 at 9:28 PM

$FATE few nuggets from Piper conference from FATE’s CEO. FT819 is a “ready when you are” type of therapy. Enrollment is increasing quickly (“faster than any other SLE therapy”) because of drug availability, efficacy, safety, and the minimal hospital stay. There will be a lot of patients to talk about in early 2026.

0 · Reply

Rocketman808 Dec. 3 at 8:29 PM

$FATE my FA called concerned about diversity in my portfolio. 😂

1 · Reply

Tonyboner Dec. 3 at 8:12 PM

$FATE Buying down here for ash

0 · Reply

Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference

Nov 13, 2025, 8:30 AM EST - 21 days ago

Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates

Nov 4, 2025, 4:01 PM EST - 4 weeks ago

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Oct 26, 2025, 11:30 AM EDT - 5 weeks ago

Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy

Aug 12, 2025, 4:01 PM EDT - 4 months ago

Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates

Jun 11, 2025, 9:00 AM EDT - 6 months ago

Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress

May 30, 2025, 4:30 PM EDT - 6 months ago

Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors

May 28, 2025, 5:54 PM EDT - 6 months ago

Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress

May 13, 2025, 4:01 PM EDT - 7 months ago

Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates

May 8, 2025, 6:22 PM EDT - 7 months ago

Fate Therapeutics: Suffering The Fate Of A Depressed Cell Therapy Sector

Apr 29, 2025, 9:25 AM EDT - 7 months ago

Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting

Apr 14, 2025, 8:00 AM EDT - 8 months ago

Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)

Mar 5, 2025, 4:01 PM EST - 9 months ago

Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Mar 4, 2025, 4:01 PM EST - 9 months ago

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Feb 14, 2025, 4:01 PM EST - 10 months ago

Fate Therapeutics to Present at Upcoming Investor Conferences

Feb 4, 2025, 7:41 PM EST - 10 months ago

Fate Therapeutics Has Promising Off-The-Shelf Cell Therapies While Looking Cheap

Dec 9, 2024, 4:01 PM EST - 1 year ago

Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus

Nov 29, 2024, 1:05 PM EST - 1 year ago

Fate Therapeutics Announces Leadership Transition

Nov 26, 2024, 4:01 PM EST - 1 year ago

Fate Therapeutics to Present at Upcoming December Investor Conferences

Nov 20, 2024, 4:34 PM EST - 1 year ago

Fate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment Options

Nov 18, 2024, 8:05 AM EST - 1 year ago

Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence

Nov 12, 2024, 4:01 PM EST - 1 year ago

Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates

Nov 9, 2024, 1:30 PM EST - 1 year ago

Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting

Nov 8, 2024, 4:01 PM EST - 1 year ago

Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting

Sep 12, 2024, 4:01 PM EDT - 1 year ago

Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference

Aug 13, 2024, 4:05 PM EDT - 1 year ago

Fate Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates

Jul 21, 2024, 5:37 AM EDT - 1 year ago

Billionaires Are Buying These 2 Beaten-Down Stocks. Are They Smart Buys for Your Portfolio?

ABCL

May 29, 2024, 4:01 PM EDT - 1 year ago

Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference

May 11, 2024, 6:12 PM EDT - 1 year ago

Fate Therapeutics, Inc. (FATE) Q1 2024 Earnings Call Transcript

May 9, 2024, 4:01 PM EDT - 1 year ago

Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates

May 9, 2024, 8:30 AM EDT - 1 year ago

Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program

May 3, 2024, 4:30 PM EDT - 1 year ago

Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting

Apr 29, 2024, 4:48 PM EDT - 1 year ago

Fate Therapeutics: As Its Rally Fizzles, We May Be Near The Bottom

Apr 29, 2024, 12:09 PM EDT - 1 year ago

Fate Therapeutics: Looking For A Potential Turnaround In 2024

Apr 22, 2024, 4:30 PM EDT - 1 year ago

Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting

Mar 19, 2024, 8:44 AM EDT - 1 year ago

Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement

Mar 1, 2024, 8:00 AM EST - 1 year ago

Fate Therapeutics to Present at Upcoming March Investor Conferences

Feb 26, 2024, 8:25 PM EST - 1 year ago

Fate Therapeutics, Inc. (FATE) Q4 2023 Earnings Call Transcript

Feb 26, 2024, 4:01 PM EST - 1 year ago

Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

Feb 15, 2024, 8:00 AM EST - 1 year ago

Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results

Dec 13, 2023, 5:00 PM EST - 2 years ago

Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 12, 2023, 12:10 PM EST - 2 years ago

Fate Therapeutics: Getting There, But Perpetually

Nov 8, 2023, 9:12 PM EST - 2 years ago

Fate Therapeutics, Inc. (FATE) Q3 2023 Earnings Call Transcript

Nov 8, 2023, 4:01 PM EST - 2 years ago

Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business Updates

Oct 25, 2023, 8:00 AM EDT - 2 years ago

Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial Results

Aug 31, 2023, 8:00 AM EDT - 2 years ago

Fate Therapeutics to Present at Upcoming September Investor Conferences

Aug 8, 2023, 11:37 PM EDT - 2 years ago

Fate Therapeutics, Inc. (FATE) Q2 2023 Earnings Call Transcript

Aug 8, 2023, 4:01 PM EDT - 2 years ago

Fate Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates

Jul 28, 2023, 8:00 AM EDT - 2 years ago

Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2023 Financial Results

Nik7777 Dec. 4 at 10:46 PM

$FATE

0 · Reply

cta7978 Dec. 4 at 10:35 PM

$FATE Anyone see any significant catalysts before Q4 data?

0 · Reply

Tonyboner Dec. 4 at 9:31 PM

$FATE

0 · Reply

cta7978 Dec. 4 at 5:54 PM

$FATE There was a big pile-in about 30 days before ACR in late September, then a sharp sell off on the data. Next pile-in later this month for Q4 data in January?

0 · Reply

JSP_Dilution_Player Dec. 4 at 5:38 PM

$IPSC $FATE $TCRX all have ASH and funds into 2027. At least one should pop by Friday or Monday

0 · Reply

Portfoliovalue1 Dec. 4 at 2:42 PM

$FATE At least priced at 300-500 million market cap with current clinical results.

0 · Reply

Nik7777 Dec. 3 at 10:19 PM

$FATE 🚀

0 · Reply

Rocketman808 Dec. 3 at 9:28 PM

0 · Reply

Rocketman808 Dec. 3 at 8:29 PM

$FATE my FA called concerned about diversity in my portfolio. 😂

1 · Reply

Tonyboner Dec. 3 at 8:12 PM

$FATE Buying down here for ash

0 · Reply

Gunflint Dec. 2 at 4:48 PM

$FATE

0 · Reply

JSP_Dilution_Player Dec. 2 at 3:56 PM

$FATE some new tutes added recently and I see Johnson and Johnson holding some shares as well $JNJ

1 · Reply

KNCourt24 Dec. 2 at 3:26 PM

$FATE There’s a reason big tutes own majority of the float(75%+) here. Also many bought around Covid so many of their S/P is $5+ min. No brainer buy especially at this level💰

0 · Reply

JSP_Dilution_Player Dec. 2 at 3:08 PM

$FATE busy pipeline too.

0 · Reply

JSP_Dilution_Player Dec. 2 at 3:07 PM

$FATE they are talking about over $100 billion market

0 · Reply

KNCourt24 Dec. 2 at 2:53 PM

$FATE added more here this one’s a gem as well as $CABA

1 · Reply

JSP_Dilution_Player Dec. 2 at 2:50 PM

$FATE cash into end of 2027. ASH data ahead.

0 · Reply

KNCourt24 Dec. 2 at 1:12 PM

$FATE Give us fireworks soon🔥

0 · Reply

Jake140 Dec. 2 at 11:48 AM

$FATE Morning All!

0 · Reply

Estimize Dec. 2 at 11:00 AM

Wall St is expecting -0.27 EPS for $FATE Q4 [Reporting 03/02 BMO] http://www.estimize.com/intro/fate?chart=historical&metric_name=eps&utm_c

0 · Reply

Iightning Dec. 2 at 2:47 AM

**1ightning® Premium Options Alert (Actionable)** **Ticker:** $FATE **Contract:** Dec 19 $3C **Entry:** 0.28 **Exit:** 0.48 **Return:** **+75.10% ROI** This is the level of accuracy our VIP desk delivers daily. If you want **institutional-grade scalps without the noise**, join us. **Unlock VIP Access → https://1ightning.com**

0 · Reply

Rocketman808 Dec. 1 at 7:20 PM

$FATE

0 · Reply

Market Cap	115.93M
Revenue (ttm)	13.63M
Net Income (ttm)	-186.26M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,366.54%
Debt to Equity Ratio	0.00

Volume	1,414,000
Avg Vol	2,328,086
Day's Range	N/A - N/A
Shares Out	115.35M
Stochastic %K	61%
Beta	2.34
Analysts	Sell
Price Target	$4.94